| Year |
Citation |
Score |
| 2024 |
George AA, John SJ, Lucero LM, Eaton JB, Jaiswal E, Christensen SB, Gajewiak J, Watkins M, Cao Y, Olivera BM, Im W, McIntosh JM, Whiteaker P. Analogs of α-conotoxin PnIC selectively inhibit α7β2- over α7-only subtype nicotinic acetylcholine receptors via a novel allosteric mechanism. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 38: e23374. PMID 38161283 DOI: 10.1096/fj.202302079 |
0.443 |
|
| 2023 |
York JM, Borghese CM, George AA, Cannatella DC, Zakon HH. A potential cost of evolving epibatidine resistance in poison frogs. Bmc Biology. 21: 144. PMID 37370119 DOI: 10.1186/s12915-023-01637-8 |
0.42 |
|
| 2023 |
Whiteaker P, George AA. Discoveries and future significance of research into amyloid-beta/α7-containing nicotinic acetylcholine receptor (nAChR) interactions. Pharmacological Research. 106743. PMID 37084859 DOI: 10.1016/j.phrs.2023.106743 |
0.411 |
|
| 2023 |
York JM, Borghese CM, George AA, Cannatella DC, Zakon HH. A potential cost of evolving epibatidine resistance in poison frogs. Biorxiv : the Preprint Server For Biology. PMID 36711899 DOI: 10.1101/2023.01.04.522789 |
0.39 |
|
| 2021 |
Weltzin MM, George AA, Lukas RJ, Whiteaker P. Sleep-related hypermotor epilepsy associated mutations uncover important kinetic roles of α4β2- nicotinic acetylcholine receptor intracellular structures. Plos One. 16: e0247825. PMID 33657187 DOI: 10.1371/journal.pone.0247825 |
0.453 |
|
| 2020 |
George AA, Vieira JM, Xavier-Jackson C, Gee MT, Cirrito JR, Bimonte-Nelson H, Picciotto MR, Lukas RJ, Whiteaker P. Implications of oligomeric amyloid-beta (oAβ42) signaling through α7β2-nicotinic acetylcholine receptors (nAChR) on basal forebrain cholinergic neuronal intrinsic excitability and cognitive decline. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 33239400 DOI: 10.1523/JNEUROSCI.0876-20.2020 |
0.346 |
|
| 2019 |
Weltzin MM, George AA, Lukas RJ, Whiteaker P. Distinctive single-channel properties of α4β2-nicotinic acetylcholine receptor isoforms. Plos One. 14: e0213143. PMID 30845161 DOI: 10.1371/Journal.Pone.0213143 |
0.451 |
|
| 2017 |
George AA, Bloy A, Miwa JM, Lindstrom JM, Lukas RJ, Whiteaker P. Isoform-specific mechanisms of α3β4*-nicotinic acetylcholine receptor modulation by the prototoxin lynx1. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 28100642 DOI: 10.1096/Fj.201600733R |
0.564 |
|
| 2015 |
Ochoa V, George AA, Nishi R, Whiteaker P. The prototoxin LYPD6B modulates heteromeric α3β4-containing nicotinic acetylcholine receptors, but not α7 homomers. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 26586467 DOI: 10.1096/Fj.15-274548 |
0.405 |
|
| 2015 |
Weltzin MM, George AA, Lukas RJ, Whiteaker P. Nocturnal frontal lobe epilepsy-associated intracellular-loop mutant subunits alter single-channel properties of α4β2-nicotinic receptor isoforms Biochemical Pharmacology. 97: 628. DOI: 10.1016/J.Bcp.2015.08.023 |
0.442 |
|
| 2014 |
Moretti M, Zoli M, George AA, Lukas RJ, Pistillo F, Maskos U, Whiteaker P, Gotti C. The novel α7β2-nicotinic acetylcholine receptor subtype is expressed in mouse and human basal forebrain: biochemical and pharmacological characterization. Molecular Pharmacology. 86: 306-17. PMID 25002271 DOI: 10.1124/Mol.114.093377 |
0.485 |
|
| 2012 |
George AA, Lucero LM, Damaj MI, Lukas RJ, Chen X, Whiteaker P. Function of human α3β4α5 nicotinic acetylcholine receptors is reduced by the α5(D398N) variant. The Journal of Biological Chemistry. 287: 25151-62. PMID 22665477 DOI: 10.1074/Jbc.M112.379339 |
0.536 |
|
| 2012 |
Murray TA, Bertrand D, Papke RL, George AA, Pantoja R, Srinivasan R, Liu Q, Wu J, Whiteaker P, Lester HA, Lukas RJ. α7β2 nicotinic acetylcholine receptors assemble, function, and are activated primarily via their α7-α7 interfaces. Molecular Pharmacology. 81: 175-88. PMID 22039094 DOI: 10.1124/Mol.111.074088 |
0.422 |
|
| 2005 |
Peng JH, Fryer JD, Hurst RS, Schroeder KM, George AA, Morrissy S, Groppi VE, Leonard SS, Lukas RJ. High-affinity epibatidine binding of functional, human alpha7-nicotinic acetylcholine receptors stably and heterologously expressed de novo in human SH-EP1 cells. The Journal of Pharmacology and Experimental Therapeutics. 313: 24-35. PMID 15590768 DOI: 10.1124/Jpet.104.079004 |
0.467 |
|
| 2004 |
Wu J, Kuo YP, George AA, Xu L, Hu J, Lukas RJ. beta-Amyloid directly inhibits human alpha4beta2-nicotinic acetylcholine receptors heterologously expressed in human SH-EP1 cells. The Journal of Biological Chemistry. 279: 37842-51. PMID 15234980 DOI: 10.1074/Jbc.M400335200 |
0.503 |
|
| 2004 |
Wu J, George AA, Schroeder KM, Xu L, Marxer-Miller S, Lucero L, Lukas RJ. Electrophysiological, pharmacological, and molecular evidence for alpha7-nicotinic acetylcholine receptors in rat midbrain dopamine neurons. The Journal of Pharmacology and Experimental Therapeutics. 311: 80-91. PMID 15178698 DOI: 10.1124/Jpet.104.070417 |
0.506 |
|
| 2004 |
Eaton JB, Peng JH, Schroeder KM, George AA, Fryer JD, Krishnan C, Buhlman L, Kuo YP, Steinlein O, Lukas RJ. Erratum: Characterization of human α4β2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells (Molecular Pharmacology (2003) 64 (1283-1294)) Molecular Pharmacology. 66. DOI: 10.1124/Mol.66.1.197 |
0.531 |
|
| 2003 |
Eaton JB, Peng JH, Schroeder KM, George AA, Fryer JD, Krishnan C, Buhlman L, Kuo YP, Steinlein O, Lukas RJ. Characterization of human alpha 4 beta 2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells. Molecular Pharmacology. 64: 1283-94. PMID 14645658 DOI: 10.1124/Mol.64.6.1283 |
0.568 |
|
| 2003 |
Zhao L, Kuo YP, George AA, Peng JH, Purandare MS, Schroeder KM, Lukas RJ, Wu J. Functional properties of homomeric, human alpha 7-nicotinic acetylcholine receptors heterologously expressed in the SH-EP1 human epithelial cell line. The Journal of Pharmacology and Experimental Therapeutics. 305: 1132-41. PMID 12626641 DOI: 10.1124/Jpet.103.048777 |
0.51 |
|
| Show low-probability matches. |